Mar 18, 2009
By:
George Koroneos, Online Content & News Editor
Pharm Exec sits down with Kathryn Metcalfe, Pfizer's new vice president of corporate reputation and policy communications to discuss the new position, the perception of pharma among laypeople, and what needs to be done to boost public opinion of the drug industry.
|
Mar 5, 2009
By:
George Koroneos, Online Content & News Editor
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
|
Mar 4, 2009
By:
George Koroneos, Online Content & News Editor
The Supreme Court ruled in favor of the plaintiff in a case that has had the pharmaceutical industry on pins and needles. The verdict hammered home the fact that even though FDA approves a drug, pharmaceutical companies are responsible for making labels as clear as possible.
|
Mar 4, 2009
By:
George Koroneos, Online Content & News Editor
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?
|
Mar 4, 2009
By:
George Koroneos, Online Content & News Editor
GlaxoSmithKline received a warning letter for use of misleading imagery in its television ad for Avodart. The Feds felt that comparing prostate size to planets might not be a good idea.
|
Feb 25, 2009
By:
George Koroneos, Online Content & News Editor
A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
